MYC and prostate cancer: To address whether EZH2 is a direct target of transcriptional activation by Myc in prostate cancer, we carried out chromatin immunoprecipitation (ChIP), and enriched Myc binding approximately 1kb and 2kb upstream of the transcription start site of EZH2, which contains a canonical E-box (Figure 3B).